SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-22-003931
Filing Date
2022-11-10
Accepted
2022-11-10 16:09:48
Documents
32
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q zk2228666.htm   iXBRL 10-Q 802116
2 EXHIBIT 31.1 exhibit_31-1.htm EX-31.1 18705
3 EXHIBIT 31.2 exhibit_31-2.htm EX-31.2 18332
4 EXHIBIT 32.1 exhibit_32-1.htm EX-32.1 7079
5 EXHIBIT 32.2 exhibit_32-2.htm EX-32.2 7192
  Complete submission text file 0001178913-22-003931.txt   2396058

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cmmb-20220930.xsd EX-101.SCH 20185
7 XBRL CALCULATION FILE cmmb-20220930_cal.xml EX-101.CAL 24953
8 XBRL DEFINITION FILE cmmb-20220930_def.xml EX-101.DEF 52300
9 XBRL LABEL FILE cmmb-20220930_lab.xml EX-101.LAB 204485
10 XBRL PRESENTATION FILE cmmb-20220930_pre.xml EX-101.PRE 104250
26 EXTRACTED XBRL INSTANCE DOCUMENT zk2228666_htm.xml XML 193018
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

IRS No.: 813676773 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38807 | Film No.: 221377208
SIC: 2834 Pharmaceutical Preparations